Compare Amylx Pharmaceuticals Inc (AMLX) vs Procter & Gamble Co (PG) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and a strong net margin of 18.44%. Recent earnings have consistently beaten expectations, and a dividend of $1.09 per share is scheduled for payment in August 2026. Analyst consensus is bullish with a price target of $161.20, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.

PG offers stability with consistent earnings beats and a reliable dividend, but premium valuations and soft demand outlook pose near-term risks. Supply chain improvements and brand partnerships provide growth catalysts, while economic sensitivity and competitive pressures remain headwinds. The stock presents a balanced opportunity for income-focused investors seeking defensive exposure amid market volatility.